NeuroNews’ top 10 most popular stories of July 2021

1023

top 10 NeuroNews JulyA new technology to help surgeons reduce the risk of aneurysm regrowth, Philips’ most recent contributions to the field of stroke care, and evidence on whether men and women respond differently to spinal cord stimulation (SCS), were of particular interest to NeuroNews’ readers last month.

1. Repeated clot retrieval attempts linked to poorer functional outcome in acute ischaemic stroke patients

Findings published in Neurology indicated that repeated clot retrieval attempts are associated with an increased rate of emboli to new territory (ENT) and greater infarct growth—resulting in poorer functional outcomes in acute ischaemic stroke patients even after successful recanalisation has been achieved.

2. Research shows new surgical technology may help reduce brain aneurysm regrowth

A new tool for treating brain aneurysms may protect artery blood flow during surgery and reduce the risk of aneurysm regrowth, according to a study presented at the Society of NeuroInterventional Surgery’s 18th annual meeting (SNIS; July 26–29 2021, Colorado Springs, USA and virtual).

A

3. Philips enrols first patient in WE-TRUST stroke study to assess new workflow approach

Royal Philips announced that the first patient has been enrolled in the WE-TRUST study at Vall d’Hebron University Hospital in Barcelona, Spain, marking the official start of this multicentre randomised controlled trial to assess if the company’s Direct to Angio Suite workflow approach can improve patient outcomes less than six hours after stroke onset.

4. Robocath, Rennes University Hospital partner with Philips France to research stroke treatments

Robocath and Rennes University Hospital announced they are launching a co-development research programme using robotics to improve treatments for stroke patients.

5. How stimulation is changing the future of mental health treatment

Daniel Månsson (Flow Neuroscience, Malmö, Sweden) outlined the benefits held by transcranial direct-current stimulation (tDCS) in the treatment of depression—and how clinical evidence supporting its use for this and other mental health indications can be expanded even further in the future.

6. Mainstay Medical launches implantable restorative neurostimulation system in USA

Mainstay Medical announced the limited US commercial launch of ReActiv8, its implantable restorative neurostimulation system to treat intractable chronic low back pain.

7. Insightec announces approval of Exablate Neuro focused ultrasound platform in Singapore

Insightec announced approval of its Exablate Neuro (Exablate 4000) platform, which uses focused ultrasound to ablate targets deep in the brain, by the Health Sciences Authority (HSA) in Singapore.

8. Cerenovus to unveil new data and showcase stroke care innovations at SNIS annual meeting

Prior to SNIS 2021, Cerenovus announced it would be showcasing its latest innovations in stroke care, as well as announcing new data during poster sessions, and featuring innovations across its ischaemic and haemorrhagic portfolios to reflect its continued commitment to changing the trajectory of stroke.

9. ASA highlights value of comprehensive, patient-centred primary care after stroke

In a new scientific statement entitled “Primary Care of Adult Patients After Stroke”, the American Stroke Association (ASA)—a division of the American Heart Association (AHA)—provided a roadmap for holistic, goal-directed and patient-centred primary care in the system for adult patients with stroke.

10. Men and women respond equally well to spinal cord and DRG stimulation despite contrasting baseline pain scores

In a study intended to explore gender differences in patients with failed back surgery syndrome (FBSS) or chronic visceral pain, men and women were shown to respond equally well to SCS and dorsal root ganglion (DRG) stimulation at follow-up—although some disparities, including “significantly lower” baseline average pain scores in male patients, were observed.


LEAVE A REPLY

Please enter your comment!
Please enter your name here